Our business model is to advance innovative ideas from concept to pre-clinical candidate drug selection. We license our products at all stages of development.
SOL784 targets the underlying disease biology of FXS and we are excited for the prospects of a drug which has the potential to provide real benefits to patients for whom there is an unmet medical need https://t.co/XJs3OPrq9M